Pharma BD Deal Intelligence
Sekisui's $265M cash acquisition of Genzyme's Diagnostics business closed as a durable carve-out—Sekisui Diagnostics still operates the platform 15 years later out of Burlington, MA, launching new products including FDA-authorized COVID/Flu tests. The integration succeeded, though no public source discloses acquisition-specific ROI or profitability to confirm financial outperformance.
Termeer frames divestiture as sharpening focus on rare disease pipeline; deal is part of broader portfolio response to manufacturing issues and Sanofi's…
Sekisui pays $265M for Genzyme's diagnostics business; Genzyme stock closed up 5 cents at $70.27, reflecting investor approval of the strategic restructuring.
The acquisition will enable Sekisui Medical to build upon this historical relationship and establish an even firmer platform for Sekisui Medical's growth…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Genzyme agreed to sell Diagnostics business to Sekisui Chemical for $265M cash. 2009 revenue $167M with ~575 employees. Closed February 1, 2011.
Assessment window: 5yr post-close.
$167M Genzyme Diagnostics 2009 revenue
Clinical chemistry reagents and rapid IVD tests are consumables used in central labs, hospitals, and physician offices to diagnose and monitor cardiovascular disease (HDL/LDL cholesterol), diabetes (HbA1c, glucose), renal function, and infectious diseases. The category is dominated by reagent volume and OEM relationships rather than patented drugs, with margins driven by scale and instrument-reagent integration.
The 2010 in vitro diagnostics (IVD) clinical chemistry reagent market was led by Roche Diagnostics, Siemens Healthineers, Abbott Diagnostics, Beckman Coulter (Danaher), and Ortho Clinical Diagnostics, with Sekisui historically a Japan-centric niche player. Genzyme's diagnostics unit — a $167M revenue business in 2009 — was a leading OEM supplier of HDL/LDL cholesterol assays, enzymes, and rapid tests for cardiovascular, diabetes, renal, and infectious disease applications. For Sekisui, which had partnered with Genzyme Diagnostics for over 15 years, the $265M acquisition vaulted it from a Japanese reagent specialist into a global diagnostics franchise with a US/EU footprint and ~575 employees. For Genzyme, the divestiture was one leg of a three-part portfolio sharpening (alongside the $925M LabCorp Genetics sale) executed under shareholder pressure ahead of Sanofi's $20.1B acquisition of Genzyme. The deal did not change competitive ranking against Roche/Siemens/Abbott but established Sekisui as a credible mid-tier IVD player with diversified geographic exposure.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sekisui Chemical Co., Ltd. / Genzyme Diagnostic Products business (this deal) | 2010 | $265M | 64 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Astra AB / Zeneca Group plc | 1998 | $35.0B | 94 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
← Browse all deals · How we score deals
More: 2010 deals · Cardiovascular deals